MedElevator Войти в исследования
← Поиск публикаций

DOI 10.4103/0028-3886.241404

Медицинская библиотека · Neurology India · 2018

Pediatric opsoclonus-myoclonus-ataxia syndrome: Experience from a tertiary care university hospital.

Huddar Akshata, Bindu Parayil S, Nagappa Madhu, Bharath Rose D, Sinha Sanjib, Mathuranath Pavagada S, Taly Arun B

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Opsoclonus-myoclonus-ataxia syndrome (OMAS) is a rare disorder; there is limited experience regarding its clinical course and therapeutic response.

AIMS AND

OBJECTIVES

To describe the clinical profile, investigations, and therapeutic outcome in pediatric OMAS.

PATIENTS AND

METHODS

Fourteen children (age: 27.1 ± 7 months; male: female = 1:2.3) suffering from OMAS seen over a period of 10 years (2006-2015) were included in the study. Their clinicodemographic profile, investigations, therapeutic outcome at follow-up, and relapses were reviewed.

RESULTS

Ten children reported antecedent events (respiratory infection: 7; gastrointestinal infection: 1; vaccination: 2). The most common referral diagnosis was acute cerebellitis (n = 8). Hypotonia (n = 9), abnormal behavior (n = 10), and neuroregression (n = 6) were also the frequent manifestations. Brain magnetic resonance imaging, cerebrospinal fluid, and urinary vanillylmandelic acid were normal in all the patients. Seven patients had an underlying tumor (abdomen: 4; thorax: 2; neck: 1) detected by ultrasound (n = 2/14), computed tomography (CT) (n = 6/12), and fluorodeoxyglucose - positron emission tomography (n = 2/2). CT scan identified the tumor in 2 patients where metaiodobenzylguanidine scintigraphy was negative. All patients received steroids for 22.3 ± 20 months (3 months to 5 years). Eight required prolonged immunomodulation (>12 months). Complete remission after follow-up of 31.3 ± 19 months (7 months to 5 years) was noted in 5 patients, whereas the rest had persisting behavioral and cognitive abnormalities. Relapses were noted in 6 patients related to intercurrent infections (n = 5) and discontinuation of steroids (n = 1). The patients presented with isolated symptoms of the full-blown syndrome during their relapses.

CONCLUSION

OMAS in children runs an indolent course requiring careful monitoring and long-term immunomodulation. An abnormal behavior is common and the outcome is variable.

Для цитирования: Huddar Akshata, Bindu Parayil S, Nagappa Madhu, Bharath Rose D, Sinha Sanjib, Mathuranath Pavagada S, Taly Arun B. Pediatric opsoclonus-myoclonus-ataxia syndrome: Experience from a tertiary care university hospital.. Neurology India. 2018. DOI: 10.4103/0028-3886.241404.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.